Targeted Genetics' Cash Dwindles as Company Fails to Secure Needed Funding | GenomeWeb

Officials from Targeted Genetics announced last week that it has not been able to raise much-needed capital, raising questions about the firm's ability to advance its priority drug-development programs.

"We maintain great belief in the promise of our adeno-associated viral … platform technology and our current product-development programs," Targeted Genetics President and CEO Susan Robinson said during a conference call held last week to discuss the company's fourth-quarter financial results.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.